AGM
CCCC icon

Alpine Global Management’s C4 Therapeutics CCCC Stock Holding History

Alpine Global Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-57,528
Closed -$266K – 210
2024
Q2 		$266K Buy
+57,528
New +$343K 0.05% 256
2023
Q1 		– Sell
-18,574
Closed -$110K – 192
2022
Q4 		$110K Buy
+18,574
New +$154K 0.04% 235

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Global Management's CCCC Position: Q3 2024 in Review

Alpine Global Management sold out of C4 Therapeutics (CCCC) in Q3 2024, closing a stake of 57,528 shares — an estimated $266K sold.

Alpine Global Management first reported a position in CCCC in Q4 2022 and held it in 2 quarters. The position peaked at $266K in Q2 2024. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

  • Alpine Global Management reported no remaining C4 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 57,528 C4 Therapeutics shares in Q3 2024, an estimated $266K.
  • Alpine Global Management first reported a position in C4 Therapeutics in Q4 2022 and held it in 2 quarters.
  • Alpine Global Management's C4 Therapeutics position peaked at $266K in Q2 2024.
  • 118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.